NASDAQ: PASG Passage BIO, Inc. 8-K

Passage Bio explores sale after FDA requires randomized trial for lead FTD program

Filed April 20, 2026 · Period ending April 20, 2026 · ~1 min read

4 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade PASG commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Generated by AI · Jun 3, 2026 2:36 AM